Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series
Child's Nervous System · 2025
DOI: 10.1007/s00381-025-06868-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Child's Nervous System, 2025. Verfasst von Lucinda Chiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurosurgery, Department of Neurosurgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinb…. Hauptthemen laut MEDLINE: Nicardipine, Vasospasm, Intracranial, Calcium Channel Blockers, Subarachnoid Hemorrhage. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Vasospasm is a potentially devastating condition that can develop in pediatric patients secondary to traumatic, inflammatory, infectious, and neoplastic etiologies and carries a high risk of morbidity and mortality (Isola et al. 2022, Krishna et al. 2005). Management is often adapted from adult to pediatric care given its relative rarity in children. There is level 3 evidence for the use of intrathecal (IT) calcium channel blocker (nicardipine) administration to treat refractory vasospasm in the adult subarachnoid hemorrhage (SAH) population. Its use has yet to be investigated in children (Krishna et al. 2005). We aim to review the safety profile and efficacy of IT nicardipine for non-traumatic SAH with refractory vasospasm at our institution.
Methods
We present a single institution retrospective series of pediatric patients treated with IT nicardipine for symptomatic vasospasm refractory to standard therapies including oral nimodipine, hyperdynamic augmentation therapies, and targeted intra-arterial therapy.
Results
Pediatric patients ( n = 3), ages 16–17 years old, admitted with non-traumatic SAH who developed severe, symptomatic, and refractory vasospasm were included. All patients presented with SAH from ruptured aneurysms. A 5-day course of IT nicardipine was initiated using a protocol adapted from our adult cerebrovascular/neurocritical care service. Decreases in peak middle cerebral artery velocity (range 61–290 cm/s) and Lindegaard ratios (range 0.3–4.2) were observed from initiation to completion of treatment.
Conclusions
IT nicardipine for pediatric non-traumatic SAH with vasospasm refractory to standard treatments was used in our small series with no complications and no new ischemic events. Clinical and radiographic effects were encouraging. Further study is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Neurological Surgery, Rush University Medical Center, Chicago, IL, USA.
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. slam@luriechildrens.org.
Zitieren
APA
Chiu, L., Plonsker, J., Villalba, N. D., DeCuypere, M., Alden, T., Scoville, J., & Lam, S. (2025). Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series. Child's Nervous System. https://doi.org/10.1007/s00381-025-06868-4
Vancouver
Chiu L, Plonsker J, Villalba ND, DeCuypere M, Alden T, Scoville J, et al. Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series. Child's Nervous System. 2025. doi:10.1007/s00381-025-06868-4
BibTeX
@article{Chiu2025,
author = {Chiu, Lucinda and Plonsker, Jillian and Villalba, Nicole Dayanara and DeCuypere, Michael and Alden, Tord and Scoville, Jonathan and Lam, Sandi},
title = {Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series},
journal = {Child's Nervous System},
year = {2025},
doi = {10.1007/s00381-025-06868-4}
}
EUVIMED